Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.
Eur J HaematolJun 14, 2026 (epub)
Cuiping Ma, Yuexia Lu, Jiahang Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the incidence of second primary malignancies (SPMs) in 9337 patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors. The pooled SPM incidence was 8% with a median follow-up of 31.5 months. The study found no significant increase in SPM risk associated with BTK inhibitors compared to controls (RR = 1.30).
Key findings
- Pooled SPM incidence in BTK inhibitor-treated patients was 8% (95% CI: 6%-11%).
- Follow-up duration was identified as the only independent predictor of SPM incidence.
- BTK inhibitors did not significantly increase SPM risk compared to controls (RR = 1.30, 95% CI: 0.95-1.78).
- SPM patterns were similar between CLL/SLL and non-CLL/SLL cohorts.
Why it matters
Understanding the risk of second primary malignancies in patients treated with BTK inhibitors is crucial for clinicians managing B-cell lymphomas, as it informs patient monitoring and risk assessment strategies.